☆ 4.5 Article

Real-Life Efficacy of Tofacitinib in Various Situations in Ulcerative Colitis: A Retrospective Worldwide Multicenter Collaborative Study

INFLAMMATORY BOWEL DISEASES (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Gastroenterology & Hepatology

Assessment of Safety and Efficacy of Tofacitinib, Stratified by Age, in Patients from the Ulcerative Colitis Clinical Program

Gary R. Lichtenstein et al.

Summary: Age is considered a risk factor for adverse events in the tofacitinib ulcerative colitis clinical program, with older individuals potentially having a higher risk of herpes zoster, malignancies (excluding nonmelanoma skin cancer), and nonmelanoma skin cancer compared to younger patients.

INFLAMMATORY BOWEL DISEASES (2023)

添加到收藏夹

Article Gastroenterology & Hepatology

Tofacitinib for the Treatment of Ulcerative Colitis: An Integrated Summary of up to 7.8 Years of Safety Data from the Global Clinical Programme

William J. Sandborn et al.

Summary: This study provides a summary of tofacitinib safety in the treatment of ulcerative colitis. The results showed a low incidence of adverse events, with stable rates in patients treated for at least 7.8 years. The incidence rates of important safety events were generally below 2.0, except for herpes zoster.

JOURNAL OF CROHNS & COLITIS (2023)

添加到收藏夹

Review Gastroenterology & Hepatology

Tofacitinib for Acute Severe Ulcerative Colitis: A Systematic Review

Casper Steenholdt et al.

Summary: This systematic review analyzed the efficacy, safety, and integration of Tofacitinib in the treatment of acute severe ulcerative colitis (ASUC). The results showed that Tofacitinib has promising results in ASUC with high short-term colectomy-free survival. However, larger and high-quality studies are still needed to further evaluate its effectiveness.

JOURNAL OF CROHNS & COLITIS (2023)

添加到收藏夹

Article Gastroenterology & Hepatology

Comparative Risk of Thrombotic and Cardiovascular Events with Tofacitinib and Anti-TNF Agents in Patients with Inflammatory Bowel Diseases

Bharati D. Kochar et al.

Summary: This retrospective cohort study using a US claims database found that tofacitinib, used to treat IBD, did not increase the risk of adverse thrombotic events compared to anti-TNF therapy.

DIGESTIVE DISEASES AND SCIENCES (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Predictors of Sustained Response With Tofacitinib Therapy in Patients With Ulcerative Colitis

William J. Sandborn et al.

Summary: Baseline characteristics can predict sustained response and remission in patients with ulcerative colitis receiving tofacitinib maintenance therapy. Patients with greater clinical improvement are more likely to maintain response or remission regardless of dose received during maintenance, highlighting the importance of a robust response to induction therapy.

INFLAMMATORY BOWEL DISEASES (2022)

添加到收藏夹

Review Gastroenterology & Hepatology

Real-World Effectiveness and Safety of Tofacitinib in Patients With Ulcerative Colitis: Systematic Review With Meta-Analysis

Carlos Taxonera et al.

Summary: This study confirms the effectiveness of tofacitinib in promoting clinical remission and corticosteroid-free remission in patients with moderate to severely active UC. It also found that tofacitinib has made progress in mucosal healing in UC treatment. Additionally, the safety profile of tofacitinib in UC treatment was found to be acceptable.

INFLAMMATORY BOWEL DISEASES (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Effectiveness of Tofacitinib for Hospitalized Patients with Acute Severe Ulcerative Colitis: Case Series

Yasi Xiao et al.

Summary: Tofacitinib may be an effective rescue therapy for refractory ASUC, according to a retrospective observational study. The study found that Tofacitinib led to clinical response and increased the rate of avoiding colectomy in hospitalized patients with ASUC.

DIGESTIVE DISEASES AND SCIENCES (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Sequential Use of High-Dose Tofacitinib After Infliximab Salvage Therapy in Acute Severe Ulcerative Colitis

Robert Gilmore et al.

Summary: This study found that high-dose tofacitinib may have a role as salvage therapy in patients with steroid-refractory ASUC.

JOURNAL OF CROHNS & COLITIS (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Tofacitinib Salvage Therapy for Children Hospitalized for Corticosteroid- and Biologic-Refractory Ulcerative Colitis

Brad D. Constant et al.

Summary: This study aimed to investigate the treatment courses and colectomy-free survival among pediatric patients treated with tofacitinib for refractory ulcerative colitis.

JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Tofacitinib in Ulcerative Colitis: Real-world Evidence From the ENEIDA Registry

Maria Chaparro et al.

Summary: The study findings indicate that tofacitinib is effective and safe in treating active ulcerative colitis. However, a significant proportion of patients discontinue the drug over time, mainly due to primary failure.

JOURNAL OF CROHNS & COLITIS (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Epidemiology and Natural History of Elderly-onset Inflammatory Bowel Disease: Results From a Territory-wide Hong Kong IBD Registry

Joyce Wing Yan Mak et al.

Summary: Elderly-onset IBD patients exhibit different clinical characteristics and disease course compared to adult-onset IBD patients, with a higher risk of infections and cancer development. These patients also have increased hospitalizations related to infections and IBD, highlighting the need for specific therapeutic strategies for this special population.

JOURNAL OF CROHNS & COLITIS (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Tofacitinib for Biologic-Experienced Hospitalized Patients With Acute Severe Ulcerative Colitis: A Retrospective Case-Control Study

Jeffrey A. Berinstein et al.

Summary: The study suggests that tofacitinib with concomitant intravenous corticosteroids may reduce the risk of colectomy in ASUC patients, especially with a dosage of 10 mg three times daily. Rates of complications and steroid dependence were similar between the tofacitinib group and controls. Prospective trials are needed to further investigate the safety and optimal dosing of tofacitinib in ASUC patients.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2021)

添加到收藏夹

Letter Gastroenterology & Hepatology

Tofacitinib in Acute Severe Ulcerative Colitis: Case Series and a Systematic Review

Anuraag Jena et al.

INFLAMMATORY BOWEL DISEASES (2021)

添加到收藏夹

Letter Gastroenterology & Hepatology

Tofacitinib in Acute Severe Ulcerative Colitis: Case Series and a Systematic Review-Authors' Reply

Carlos Taxonera et al.

INFLAMMATORY BOWEL DISEASES (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Comparison of outcomes of cyclosporine A and infliximab for steroid-refractory acute severe ulcerative colitis

Eun Mi Song et al.

Summary: Through retrospective review of 121 Korean patients with SR-ASUC, it was found that there were no significant differences in the rates of treatment failure and colectomy at 3 months between the CsA and IFX treatment groups. Additionally, prior use of azathioprine and Mayo score at the time of rescue therapy were both associated with treatment failure or colectomy within 3 months.

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Tofacitinib as salvage therapy for 55 patients hospitalised with refractory severe ulcerative colitis: A GETAID cohort

Mathieu Uzzan et al.

Summary: The study evaluated the effectiveness and safety of tofacitinib as rescue therapy in UC patients hospitalized for flare. Results showed high rates of colectomy-free survival, clinical response, and clinical remission with tofacitinib treatment. Safety profile of tofacitinib was favorable with no deaths observed and only a few adverse events reported. Further validation in controlled trials is needed to confirm the promising potential of tofacitinib in hospitalized UC patients.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2021)

添加到收藏夹

Review Gastroenterology & Hepatology

Real-world experience with tofacitinib in ulcerative colitis: a systematic review and meta-analysis

Laura A. Lucaciu et al.

Summary: This study summarized observational data on the effectiveness and safety of tofacitinib in moderate to severe ulcerative colitis patients, indicating favorable induction and maintenance of clinical response and remission, but with a considerable proportion of patients experiencing adverse events and discontinuing the treatment.

THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Tofacitinib Treatment Is Associated With Modest and Reversible Increases in Serum Lipids in Patients With Ulcerative Colitis

Bruce E. Sands et al.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2020)

添加到收藏夹

Article Gastroenterology & Hepatology

Tofacitinib for Rescue Therapy in Acute Severe Ulcerative Colitis: A Real-world Experience

Prashant Kotwani et al.

JOURNAL OF CROHNS & COLITIS (2020)

添加到收藏夹

Article Gastroenterology & Hepatology

Real-world Effectiveness of Tofacitinib for Moderate to Severe Ulcerative Colitis: A Multicentre UK Experience

Sailish Honap et al.

JOURNAL OF CROHNS & COLITIS (2020)

添加到收藏夹

Letter Gastroenterology & Hepatology

Tofacitinib in Acute Severe Ulcerative Colitis-A Real-World Tertiary Center Experience

Sailish Honap et al.

INFLAMMATORY BOWEL DISEASES (2020)

添加到收藏夹

Article Gastroenterology & Hepatology

Vedolizumab is effective and safe in elderly inflammatory bowel disease patients: a binational, multicenter, retrospective cohort study

Nathaniel Aviv Cohen et al.

UNITED EUROPEAN GASTROENTEROLOGY JOURNAL (2020)

添加到收藏夹

Article Gastroenterology & Hepatology

Real-World Experience with Tofacitinib in IBD at a Tertiary Center

Roni Weisshof et al.

DIGESTIVE DISEASES AND SCIENCES (2019)

添加到收藏夹

Article Gastroenterology & Hepatology

Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme

William J. Sandborn et al.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2019)

添加到收藏夹

Letter Gastroenterology & Hepatology

Efficacy of Induction Therapy With High-Intensity Tofacitinib in 4 Patients With Acute Severe Ulcerative Colitis

Jeffrey A. Berinstein et al.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2019)

添加到收藏夹

Article Gastroenterology & Hepatology

Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical Trials

William J. Sandborn et al.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2019)

添加到收藏夹

Article Rheumatology

Comparative Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients Receiving Tofacitinib Versus Those Receiving Tumor Necrosis Factor Inhibitors: An Observational Cohort Study

Rishi J. Desai et al.

ARTHRITIS & RHEUMATOLOGY (2019)

添加到收藏夹

Review Gastroenterology & Hepatology

Tofacitinib for the treatment of moderately to severely active ulcerative colitis: a systematic review, network meta-analysis and economic evaluation

Christoph Lohan et al.

BMJ OPEN GASTROENTEROLOGY (2019)

添加到收藏夹

Article Dermatology

Tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: long-term safety and efficacy in an open-label extension study

F. Valenzuela et al.

BRITISH JOURNAL OF DERMATOLOGY (2018)

添加到收藏夹

Article Immunology

Tofacitinib for the treatment of ulcerative colitis

Agnes Fernandez-Clotet et al.

EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2018)

添加到收藏夹

Article Medicine, General & Internal

Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis

William J. Sandborn et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

添加到收藏夹

Article Gastroenterology & Hepatology

Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomised trial

John G. Williams et al.

LANCET GASTROENTEROLOGY & HEPATOLOGY (2016)

添加到收藏夹

Article Gastroenterology & Hepatology

Bolus administration of steroid therapy is more favorable than the conventional use in preventing decrease of bone density and the increase of body fat percentage in patients with inflammatory bowel disease

Klaudia Farkas et al.

JOURNAL OF CROHNS & COLITIS (2014)

添加到收藏夹

Article Gastroenterology & Hepatology

Long-term increase in serum cholesterol levels in ulcerative colitis patients treated with cyclosporine: an underdiagnosed side effect frequently associated with other drug-related complications

Anita Balint et al.

SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2014)

添加到收藏夹

Article Rheumatology

Janus kinase inhibitors in autoimmune diseases

John J. O'Shea et al.

ANNALS OF THE RHEUMATIC DISEASES (2013)

添加到收藏夹

Article Gastroenterology & Hepatology

Older Age Is Associated with Higher Rate of Discontinuation of Anti-TNF Therapy in Patients with Inflammatory Bowel Disease

Amit Desai et al.

INFLAMMATORY BOWEL DISEASES (2013)

添加到收藏夹

Article Medicine, General & Internal

Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial

David Laharie et al.

LANCET (2012)

添加到收藏夹

Article Gastroenterology & Hepatology

The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications

J. Satsangi et al.

GUT (2006)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.